Search

Your search keyword '"Baynes, C"' showing total 4 results
Start Over Author "Baynes, C" Language undetermined
4 results on '"Baynes, C"'

1. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women

Author

Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Luccarini, C., Wahlstrom, C., Pooley, K.A., Parsons, M.T., Fortuno, C., Wang, Q., Bolla, M.K., Dennis, J., Keeman, R., Alonso, M.R., Alvarez, N., Herraez, B., Fernandez, V., Nunez-Torres, R., Osorio, A., Valcich, J., Li, M., Torngren, T., Harrington, P.A., Baynes, C., Conroy, D.M., Decker, B., Fachal, L., Mavaddat, N., Ahearn, T., Aittomaki, K., Antonenkova, N.N., Arnold, N., Arveux, P., Ausems, M.G.E.M., Auvinen, P., Becher, H., Beckmann, M.W., Behrens, S., Bermisheva, M., Bialkowska, K., Blomqvist, C., Bogdanova, N.V., Bogdanova-Markov, N., Bojesen, S.E., Bonanni, B., Borresen-Dale, A.L., Brauch, H., Bremer, M., Briceno, I., Bruning, T., Burwinkel, B., Cameron, D.A., Camp, N.J., Campbell, A., Carracedo, A., Castelao, J.E., Cessna, M.H., Chanock, S.J., Christiansen, H., Collee, J.M., Cordina-Duverger, E., Cornelissen, S., Czene, K., Dork, T., Ekici, A.B., Engel, C., Eriksson, M., Fasching, P.A., Figueroa, J., Flyger, H., Forsti, A., Gabrielson, M., Gago-Dominguez, M., Georgoulias, V., Gil, F., Giles, G.G., Glendon, G., Garcia, E.B.G., Alnaes, G.I.G., Guenel, P., Hadjisavvas, A., Haeberle, L., Hahnen, E., Hall, P., Hamann, U., Harkness, E.F., Hartikainen, J.M., Hartman, M., He, W., Heemskerk-Gerritsen, B.A.M., Hillemanns, P., Hogervorst, F.B.L., Hollestelle, A., Ho, W.K., Hooning, M.J., Howell, A., Humphreys, K., Idris, F., Jakubowska, A., Jung, A., Kapoor, P.M., Kerin, M.J., Khusnutdinova, E., Kim, S.W., Ko, Y.D., Kosma, V.M., Kristensen, V.N., Kyriacou, K., Lakeman, I.M.M., Lee, J.W., Lee, M.H., Li, J.M., Lindblom, A., W.Y. lo, Loizidou, M.A., Lophatananon, A., Lubinski, J., MacInnis, R.J., Madsen, M.J., Mannermaa, A., Manoochehri, M., Manoukian, S., Margolin, S., Martinez, M.E., Maurer, T., Mavroudis, D., McLean, C., Meindl, A., Mensenkamp, A.R., Michailidou, K., Miller, N., Taib, N.A.M., Muir, K., Mulligan, A.M., Nevanlinna, H., Newman, W.G., Nordestgaard, B.G., Ng, P.S., Oosterwijk, J.C., Park, S.K., Park-Simon, T.W., Perez, J.I.A., Peterlongo, P., Porteous, D.J., Prajzendanc, K., Prokofyeva, D., Radice, P., Rashid, M.U., Rhenius, V., Rookus, M.A., Rudiger, T., Saloustros, E., Sawyer, E.J., Schmutzler, R.K., Schneeweiss, A., Schurmann, P., Shah, M., Sohn, C., Southey, M.C., Surowy, H., Suvanto, M., Thanasitthichai, S., Tomlinson, I., Torres, D., Truong, T., Tzardi, M., Valova, Y., Asperen, C.J. van, Dam, R.M. van, Ouweland, A.M.W. van den, Kolk, L.E. van der, Veen, E.M. van, Wendt, C., Williams, J.A., Yang, X.H.R., Yoon, S.Y., Zamora, M.P., Evans, D.G., Hoya, M. de la, Simard, J., Antoniou, A.C., Borg, A., Andrulis, I.L., Chang-Claude, J., Garcia-Closas, M., Chenevix-Trench, G., Milne, R.L., Pharoah, P.D.P., Schmidt, M.K., Spurdle, A.B., Vreeswijk, M.P.G., Benitez, J., Dunning, A.M., Kvist, A., Teo, S.H., Devilee, P., Easton, D.F., Breast Canc Assoc Consortium, Erasmus MC other, Medical Oncology, Clinical Genetics, Keeman, Renske [0000-0002-5452-9933], Decker, Brennan [0000-0003-4516-7421], Eriksson, Mikael [0000-0001-8135-4270], Martinez, Maria Elena [0000-0002-6728-1834], Surowy, Harald [0000-0002-3595-9188], Pharoah, Paul DP [0000-0001-8494-732X], Apollo - University of Cambridge Repository, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: DA KG Polikliniek (9), and Klinische Genetica

Subjects
Adult, Risk, Oncology, medicine.medical_specialty, Adolescent, PALB2, Genetic counseling, Genes, BRCA2, Mutation, Missense, Genes, BRCA1, Estrogen receptor, Breast Neoplasms, 030204 cardiovascular system & hematology, OVARIAN-CANCER, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, Odds Ratio, medicine, Humans, Genetic Predisposition to Disease, 030212 general & internal medicine, skin and connective tissue diseases, CHEK2, Aged, Genetic testing, Genetic association, Aged, 80 and over, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], medicine.diagnostic_test, MUTATIONS, business.industry, Age Factors, Genetic Variation, Sequence Analysis, DNA, General Medicine, Odds ratio, Middle Aged, BRCA1, medicine.disease, 3. Good health, Logistic Models, Female, business
Abstract

BACKGROUNDGenetic testing for breast cancer susceptibility is widely used, but for many genes,evidence of an association with breast cancer is weak, underlying risk estimatesare imprecise, and reliable subtype-specific risk estimates are lacking.METHODSWe used a panel of 34 putative susceptibility genes to perform sequencing onsamples from 60,466 women with breast cancer and 53,461 controls. In separateanalyses for protein-truncating variants and rare missense variants in these genes,we estimated odds ratios for breast cancer overall and tumor subtypes. We evaluatedmissense-variant associations according to domain and classification of pathogenicity.RESULTSProtein-truncating variants in 5 genes (ATM, BRCA1, BRCA2, CHEK2, and PALB2)were associated with a risk of breast cancer overall with a P value of less than0.0001. Protein-truncating variants in 4 other genes (BARD1, RAD51C, RAD51D,and TP53) were associated with a risk of breast cancer overall with a P value ofless than 0.05 and a Bayesian false-discovery probability of less than 0.05. Forprotein-truncating variants in 19 of the remaining 25 genes, the upper limit ofthe 95% confidence interval of the odds ratio for breast cancer overall was lessthan 2.0. For protein-truncating variants in ATM and CHEK2, odds ratios werehigher for estrogen receptor (ER)–positive disease than for ER-negative disease;for protein-truncating variants in BARD1, BRCA1, BRCA2, PALB2, RAD51C, andRAD51D, odds ratios were higher for ER-negative disease than for ER-positivedisease. Rare missense variants (in aggregate) in ATM, CHEK2, and TP53 wereassociated with a risk of breast cancer overall with a P value of less than 0.001.For BRCA1, BRCA2, and TP53, missense variants (in aggregate) that would be classified as pathogenic according to standard criteria were associated with a riskof breast cancer overall, with the risk being similar to that of protein-truncatingvariants.CONCLUSIONSThe results of this study define the genes that are most clinically useful for inclusion on panels for the prediction of breast cancer risk, as well as provide estimatesof the risks associated with protein-truncating variants, to guide genetic counseling. (Funded by European Union Horizon 2020 programs and others.)

Published
2021

2. Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis

Author

Shu, X., Wu, L., Khankari, N.K., Shu, X.O., Wang, T.J., Michailidou, K., Bolla, M.K., Wang, Q., Dennis, J., Milne, R.L., Schmidt, M.K., Pharoah, P.D.P., Andrulis, I.L., Hunter, D.J., Simard, J., Easton, D.F., Zheng, W., Alicia, B.F.J., Anton-Culver, H., Antonenkova, N.N., Arndt, V., Aronson, K.J., Auer, P.L., Barrdahl, M., Baynes, C., Freeman, L.E.B., Beckmann, M.W., Behrens, S., Benitez, J., Bermisheva, M., Blomqvist, C., Bogdanova, N.V., Bojesen, S.E., Brauch, H., Brenner, H., Brinton, L., Broberg, P., Brucker, S.Y., Bruning, T., Burwinkel, B., Cai, Q.Y., Caldes, T., Canzian, F., Carter, B.D., Castelao, J.E., Chang-Claude, J., Chenevix-Trench, G., Cheng, T.Y.D., Clarke, C.L., Conroy, D.M., Couch, F.J., Cox, D.G., Cox, A., Cross, S.S., Cunningham, J.M., Czene, K., Daly, M.B., Doheny, K.F., Dork, T., dos-Santos-Silva, I., Dumont, M., Dunning, A.M., Dwek, M., Earp, H.S., Eccles, D.M., Eliassen, A.H., Engel, C., Eriksson, M., Evans, D.G., Fachal, L., Fasching, P.A., Figueroa, J., Fletcher, O., Flyger, H., Fritschi, L., Gabrielson, M., Gago-Dominguez, M., Gapstur, S.M., Garcia-Closas, M., Gaudet, M.M., Ghoussaini, M., Giles, G.G., Goldberg, M.S., Goldgar, D.E., Gonzalez-Neira, A., Guenel, P., Hahnen, E., Haiman, C.A., Hakansson, N., Hall, P., Hallberg, E., Hamann, U., Harrington, P., He, W., Hein, A., Hicks, B., Hillemanns, P., Hogervorst, F.B., Hollestelle, A., Hoover, R.N., Hopper, J.L., Howell, A., Huang, G., Jakubowska, A., Janni, W., John, E.M., Johnson, N., Jones, K., Jung, A., Kaaks, R., Kabisch, M., Kerin, M.J., Khusnutdinova, E., Kitahara, C.M., Kosma, V.M., Koutros, S., Kraft, P., Kristensen, V.N., Lambrechts, D., Marchand, L. le, Lindstrom, S., Linet, M.S., Lissowska, J., Loibl, S., Lubinski, J., Luccarini, C., Lux, M.P., Maishman, T., Kostovska, I.M., Mannermaa, A., Manoukian, S., Manson, J.E., Margolin, S., Mavroudis, D., Meijers-Heijboer, H., Meindl, A., Menon, U., Meyer, J., Mulligan, A.M., Neuhausen, S.L., Nevanlinna, H., Neven, P., Newman, W.T., Nielsen, S.F., Nordestgaard, B.G., Olopade, O.I., Olshan, A.F., Olson, J.E., Olsson, H., Olswol, C., Orr, N., Perou, C.M., Peto, J., Plaseska-Karanfilska, D., Prentice, R., Presneau, N., Pylkas, K., Rack, B., Radice, P., Rahman, N., Rennert, G., Rennert, H.S., Romero, A., Romm, J., Saloustros, E., Sandler, D.P., Sawyer, E.J., Schmutzler, R.K., Schneeweiss, A., Scott, R.J., Scott, C., Seal, S., Seynaeve, C., Smeets, A., Southey, M.C., Spinelli, J.J., Stone, J., Surowy, H., Swerdlow, A.J., Tamimi, R., Tapper, W., Taylor, J.A., Terry, M.B., Tessier, D.C., Thone, K., Tollenaar, R.A.E.M., Torres, D., Troester, M.A., Truong, T., Untch, M., Vachon, C., Berg, D. van den, Ouweland, A.M.W. van den, Veen, E.M. van, Vincent, D., Waisfisz, Q., Weinberg, C.R., Wendt, C., Whittemore, A.S., Wildiers, H., Winqvist, R., Wolk, A., Xia, L., Yang, X.H.R., Ziogas, A., Ziv, E., Breast Canc Assoc Consortium, NBCS Collaborators, and Clinical Genetics

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, insulin, obesity, Epidemiology, medicine.medical_treatment, Mendelian randomization analysis, Type 2 diabetes, VARIANTS, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Waist–hip ratio, FATNESS, SDG 3 - Good Health and Well-being, Mendelian Randomization, Internal medicine, Diabetes mellitus, medicine, genetics, COHORT, 030212 general & internal medicine, glucose, Public, Environmental & Occupational Health, 2. Zero hunger, Science & Technology, business.industry, Insulin, Cancer, PATHWAYS, General Medicine, Odds ratio, INSTRUMENTS, medicine.disease, 3. Good health, BODY-MASS INDEX, INSIGHTS, 030104 developmental biology, FASTING PLASMA-GLUCOSE, business, Body mass index, Life Sciences & Biomedicine, RESISTANCE, EXPENDITURE
Abstract

Background In addition to the established association between general obesity and breast cancer risk, central obesity and circulating fasting insulin and glucose have been linked to the development of this common malignancy. Findings from previous studies, however, have been inconsistent, and the nature of the associations is unclear. Methods We conducted Mendelian randomization analyses to evaluate the association of breast cancer risk, using genetic instruments, with fasting insulin, fasting glucose, 2-h glucose, body mass index (BMI) and BMI-adjusted waist-hip-ratio (WHRadj BMI). We first confirmed the association of these instruments with type 2 diabetes risk in a large diabetes genome-wide association study consortium. We then investigated their associations with breast cancer risk using individual-level data obtained from 98 842 cases and 83 464 controls of European descent in the Breast Cancer Association Consortium. Results All sets of instruments were associated with risk of type 2 diabetes. Associations with breast cancer risk were found for genetically predicted fasting insulin [odds ratio (OR) = 1.71 per standard deviation (SD) increase, 95% confidence interval (CI) = 1.26-2.31, p = 5.09 × 10–4], 2-h glucose (OR = 1.80 per SD increase, 95% CI = 1.3 0-2.49, p = 4.02 × 10–4), BMI (OR = 0.70 per 5-unit increase, 95% CI = 0.65-0.76, p = 5.05 × 10–19) and WHRadj BMI (OR = 0.85, 95% CI = 0.79-0.91, p = 9.22 × 10–6). Stratified analyses showed that genetically predicted fasting insulin was more closely related to risk of estrogen-receptor [ER]-positive cancer, whereas the associations with instruments of 2-h glucose, BMI and WHRadj BMI were consistent regardless of age, menopausal status, estrogen receptor status and family history of breast cancer. Conclusions We confirmed the previously reported inverse association of genetically predicted BMI with breast cancer risk, and showed a positive association of genetically predicted fasting insulin and 2-h glucose and an inverse association of WHRadj BMI with breast cancer risk. Our study suggests that genetically determined obesity and glucose/insulin-related traits have an important role in the aetiology of breast cancer.

Published
2019

3. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

Author

Easton, D.F., Lesueur, F., Decker, B., Michailidou, K., Li, J., Allen, J., Luccarini, C., Pooley, K.A., Shah, M., Bolla, M.K., Wang, Q., Dennis, J., Ahmad, J., Thompson, E.R., Damiola, F., Pertesi, M., Voegele, C., Mebirouk, N., Robinot, N., Durand, G., Forey, N., Luben, R.N., Ahmed, S., Aittomaki, K., Anton-Culver, H., Arndt, V., Baynes, C., Beckman, M.W., Benitez, J., Berg, D. van den, Blot, W.J., Bogdanova, N.V., Bojesen, S.E., Brenner, H., Chang-Claude, J., Chia, K.S., Choi, J.Y., Conroy, D.M., Cox, A., Cross, S.S., Czene, K., Darabi, H., Devilee, P., Eriksson, M., Fasching, P.A., Figueroa, J., Flyger, H., Fostira, F., Garcia-Closas, M., Giles, G.G., Glendon, G., Gonzalez-Neira, A., Guenel, P., Haiman, C.A., Hall, P., Hart, S.N., Hartman, M., Hooning, M.J., Hsiung, C.N., Ito, H., Jakubowska, A., James, P.A., John, E.M., Johnson, N., Jones, M., Kabisch, M., Kang, D., Kosma, V.M., Kristensen, V., Lambrechts, D., Li, N., Lindblom, A., Long, J., Lophatananon, A., Lubinski, J., Mannermaa, A., Manoukian, S., Margolin, S., Matsuo, K., Meindl, A., Mitchell, G., Muir, K., Nevelsteen, I., Ouweland, A. van den, Peterlongo, P., Phuah, S.Y., Pylkas, K., Rowley, S.M., Sangrajrang, S., Schmutzler, R.K., Shen, C.Y., Shu, X.O., Southey, M.C., Surowy, H., Swerdlow, A., Teo, S.H., Tollenaar, R.A.E.M., Tomlinson, I., Torres, D., Truong, T., Vachon, C., Verhoef, S., Wong-Brown, M., Zheng, W., Zheng, Y., Nevanlinna, H., Scott, R.J., Andrulis, I.L., Wu, A.H., Hopper, J.L., Couch, F.J., Winqvist, R., Burwinkel, B., Sawyer, E.J., Schmidt, M.K., Rudolph, A., Dork, T., Brauch, H., Hamann, U., Neuhausen, S.L., Milne, R.L., Fletcher, O., Pharoah, P.D.P., Campbell, I.G., Dunning, A.M., Calvez-Kelm, F. le, Goldgar, D.E., Tavtigian, S.V., Chenevix-Trench, G., Australian Ovarian Canc Study Grp, kConFab Investigators, Lifepool Investigators, NBCS Investigators, Luben, Robert N [0000-0002-5088-6343], Apollo - University of Cambridge Repository, Clinical Genetics, Medical Oncology, and Molecular Genetics

Subjects
0301 basic medicine, Bioinformatics, Medical and Health Sciences, Cohort Studies, Breast cancer screening, 0302 clinical medicine, Medizinische Fakultät, Missense mutation, Genetics (clinical), Genetics & Heredity, education.field_of_study, medicine.diagnostic_test, Biological Sciences, Middle Aged, Fanconi Anemia Complementation Group Proteins, 3. Good health, ddc, DNA-Binding Proteins, 030220 oncology & carcinogenesis, kConFab Investigators, Female, RNA Helicases, Australian Ovarian Cancer Study Group, Adult, Risk, medicine.medical_specialty, PALB2, Population, European Continental Ancestry Group, Breast Neoplasms, NBCS Investigators, Biology, Article, White People, 03 medical and health sciences, Breast cancer, SDG 3 - Good Health and Well-being, Molecular genetics, Genetics, medicine, breast [Cancer], Humans, Genetic Predisposition to Disease, Genetic Testing, ddc:610, Allele, education, Genetic Association Studies, Aged, Cancer: breast, BRIP1, medicine.disease, 030104 developmental biology, Lifepool Investigators, Mutation
Abstract

Background: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction. Methods: We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia. Results: The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75). Conclusions: These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels.

Published
2015

4. Discussion. Experiments on the Strength of Cement, Chiefly in Reference to the Portland Cement Used in the Southern Main Drainage Works

Author

Hemans, G. W., Aird, J., Bateman, J. F., Maudslay, H., Redman, J. B., Code, J., Bevan, T., Francis, C. L., Druce, E., Fox, C., Jennings, J., White, G. F., Dines, G., Lane, C. B., Ridley, T. D., Brereton, R. P., Bazalgette, J. W., Hartley, C., Baynes, C., Russell, S., Rawlinson, R., Bramwell, F. J., Grant, J., and Curtis, C.

Abstract

n/a

Published
1865

Catalog

Books, media, physical & digital resources
See catalog results